Veeva Digital Clinical Trials Survey Report

Ad - Bora Pharmaceuticals

Veeva released the largest survey on digital trials examining the opportunities and implications of decentralized approaches on clinical trials by gathering the experiences and opinions of more than 280 clinical leaders worldwide. In case you find it useful for any stories you or your team are writing in the future, I’ve shared below some key takeaways.

Rapid shift to decentralized trials: Rapid adoption of decentralized technologies accelerated to enable remote execution during COVID-19. Today, most (87%) use some type of decentralized technology, up 59 percentage points from pre-pandemic (28%).

More clinical apps: Companies added an average of four new applications to their clinical landscape, leading to issues with data collection and stakeholder collaboration and impacting study quality and speed.

Fragmented technology is causing challenges: Nearly all sponsors and CROs (99%) report significant challenges with decentralized trials. Major changes are happening to address lack of site technology adoption (70%) and increased burden for technology-averse patients (50%).

Future transition to completely Digital Trials: Most respondents (95%) say they have initiatives underway to establish a digital foundation for patient and site-centric trials that will better support sites, improve data sharing and collaboration, and eliminate silos through a connected network. Respondents are accelerating digital transformation to advance toward paperless trials.

You can read the full report here.